|Chemical and physical data|
|Molar mass||145385.35 g·mol−1|
|(what is this?)|
Johnson & Johnson licensed the drug from Amgen in a deal valued at around US$425 million in 2008. In 2016 Johnson & Johnson discontinued all phase III trials of fulranumab and returned the rights to its originator. The company said the decision was based on "strategic portfolio prioritisation and was not based on any emerging safety concerns from the phase III clinical studies with fulranumab" in osteoarthritic pain.
- Verburg K (12 March 2012). "Monoclonal Antibodies Targeted Against Nerve Growth Factor For the Treatment of Chronic Pain" (PDF). Medicines Development Group, Pfizer Inc., Arthritis Advisory Committee Meeting. U.S. Food and Drug Administration. Archived from the original (PDF) on 20 October 2016.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab" (PDF). American Medical Association. Archived from the original (PDF) on 24 March 2012.
- Reynolds DS (2013). "Chapter 10 Pain Management Companies". In Allerton C (ed.). Pain therapeutics: current and future treatment paradigms. Cambridge: Royal Society of Chemistry. p. 318. ISBN 978-1-84973-771-5.
- Taylor P (4 April 2016). "J&J drops NGF blocker fulranumab". PMLiVE.